Yale University

Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model.

TitleCost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model.
Publication TypeJournal Article
Year of Publication2007
AuthorsWu, Ann C., David A. Paltiel, Karen M. Kuntz, Scott T. Weiss, and Anne L. Fuhlbrigge
JournalThe Journal of allergy and clinical immunology
Volume120
Issue5
Pagination1146-52
Date Published2007 Nov
ISSN1097-6825
KeywordsAnti-Allergic Agents, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Asthma, Cost-Benefit Analysis, Humans, Models, Theoretical, Severity of Illness Index
AbstractOmalizumab (trade name Xolair) is approved by the US Food and Drug Administration for treatment of moderate-to-severe allergic asthma. Given the high acquisition cost of omalizumab, its role and cost-effectiveness in disease management require definition.
DOI10.1111/j.1524-4733.2010.00763.x
Alternate JournalJ. Allergy Clin. Immunol.

External Links